CytoSorbents continues to reduce losses while growing revenue, though working from a substantially depleted equity base following prior period restatements.
The company is demonstrating operational progress with improved revenue growth and meaningfully reduced net losses, suggesting better business fundamentals. However, the significantly weakened balance sheet position and removal of restatement language indicates the company is still recovering from prior accounting issues that impacted investor confidence.
CTSO showed encouraging operational momentum with revenue growing substantially and net losses improving meaningfully year-over-year. The company strengthened its liquidity position with cash roughly doubling and inventory levels expanding significantly. However, stockholders' equity declined nearly 47%, reflecting the lasting impact of prior period corrections, though the improving cash flow metrics suggest the business fundamentals are stabilizing.
Inventory surged 93.2% — growing significantly faster than typical sales pace; potential demand softening or supply chain overcorrection.
Cash position surged 90.5% — strong cash generation or capital raise providing significant financial cushion.
Net income grew 60.4% — bottom-line growth signals improving overall business health.
Strong top-line growth of 48.5% — accelerating demand or successful expansion into new markets.
Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.
Capex reduced 42.3% — investment cycle winding down or capital discipline; may improve near-term free cash flow.
Operating cash flow grew 14.2% — strong conversion of earnings to cash, healthy business fundamentals.
Operating income improving — cost discipline or growing revenue base absorbing fixed costs.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →